A Agilent Technologies Inc.

Agilent 2024 Early Career Professor Award Presented to Adeyemi Adeleye

(NYSE: A) announced today that , has received the Agilent 2024 Early Career Professor Award for his contribution to environmental health and sustainability, developing green analytical technologies, methods, or laboratory working environments. Dr. Adeleye is an assistant professor in the Department of Earth and Environmental Engineering at .

The 2024 award focused on contributions to academic research in sustainability and green chemistry. Dr. Adeleye’s research focuses on improving environmental health and sustainability through green approaches, and specifically, using engineered nanoparticles made of earth-abundant, essential elements such as iron, sulfur, and silicon to remediate environmental matrices contaminated with persistent pollutants like arsenic, lead, and per- and polyfluoroalkyl substances (PFAS). Additionally, Dr. Adeleye is studying ways to combine remediation with carbon sequestration in soil to reduce the environmental impact of these approaches.

“I am deeply honored and grateful to receive this esteemed award, which recognizes my research group’s efforts and inspires us to continue striving for excellence,” said Dr. Adeleye. “Persistent environmental contaminants, like heavy metals, pose a significant threat to food safety and human health. "We will continue to expand our understanding of how heavy metals interact with engineered surfaces in natural environments, supporting our long-term goal of developing sustainable solutions to heavy metal contamination. The support from Agilent will undoubtedly help us achieve this important ambition.”

“Agilent is committed to advancing environmental sustainability and empowering innovation that accelerates the development of eco-friendly solutions by supporting researchers who are pioneering green analytical technologies and sustainable laboratory practices,” said Nahid Chalyavi, associate vice president of University Relations and External Research at Agilent. “This year’s award recipient, Dr. Adeleye, is at the forefront of integrating environmental chemistry, engineering, and material science. His research focuses on understanding the reactions between pollutants and reactive surfaces in environmental systems and applying this knowledge to remediate polluted environments.”

Dr. Adeleye’s research supports the effort of the US Food and Drug Administration (FDA) and the US Department of Agriculture (USDA) to tackle the widespread occurrence of toxic heavy metals in crop-based foods through the “Closer-to-Zero” Initiative. The National Science Foundation (NSF) and the Centers for Disease Control and Prevention (CDC) have also supported his work.

The Agilent Early Career Professor Award is an annual program that recognizes and supports promising research from professors who, early in their careers, show outstanding potential for future research in areas of importance to the communities Agilent serves. This award underscores Agilent's commitment to furthering research through the company's products and services, financial support, and collaborative engagement by Agilent scientists and engineers. Further information about the program is available at .

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.85 billion in fiscal 2022 and employs approximately 18,000 people worldwide. Information about Agilent is available at . To receive the latest Agilent news, please subscribe to the Agilent . Follow Agilent on and .

EN
20/11/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Agilent Technologies Inc.

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

 PRESS RELEASE

Agilent xCELLigence RTCA Instrumentation Applied in Recent FDA Approva...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) is pleased to announce its role in supporting Autolus Therapeutics’ , a recently approved CAR T therapy. Agilent's advanced cell analysis instrumentation, specifically the technology, was applied in developing and validating AUCATZYL. The xCELLigence RTCA technology supported the development and implementation of the potency assay. By providing precise and reliable cell analysis solutions, Agilent assisted Autolus in achieving the high standards required for FDA approval. Dr. Xiaobo Wang, Vice President and General Manager of the Cell Functio...

 PRESS RELEASE

CORRECTING and REPLACING Agilent to Showcase Next-Generation Digital P...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- Please replace the release with the following corrected version due to multiple revisions to the fifth paragraph. The updated release reads: AGILENT TO SHOWCASE NEXT-GENERATION DIGITAL PATHOLOGY SOLUTIONS AT USCAP 2025 (NYSE: A) is excited to announce its participation at the upcoming , which will be held March 22-27, 2025, in Boston. At the conference, Agilent will highlight innovative digital pathology solutions designed to enhance diagnostic accuracy and efficiency. In pathology, Agilent offers comprehensive tissue diagnostic solutions for analyzi...

 PRESS RELEASE

Agilent Research Catalyst Award Presented to Columbia University for P...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) today announced that has received an Agilent Research Catalyst (ARC) Award on behalf of , an internationally recognized researcher and physician-scientist specializing in bone marrow transplant (BMT) and cancer cellular immunotherapy. Dr. Muranski is the Director of Cellular Immunotherapy Laboratory at Columbia University Irving Medical Center. He is also an Assistant Professor of Medicine at Columbia University Medical Center, a principal investigator at the Columbia Center for Translational Immunology (CCTI), and a member of the Herbert Irv...

 PRESS RELEASE

Agilent PD-L1 IHC 28-8 pharmDx Receives EU IVDR Certification as a Com...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) today announced its kit has received two new companion diagnostic indications approvals under EU IVDR1, expanding the eligibility of treatment to early-stage non-small cell lung cancer (NSCLC) and previously untreated advanced melanoma patients. These two new indications bring the total indications launched in Europe for PD-L1 IHC 28-8 pharmDx to nine. PD-L1 IHC 28-8 pharmDx is approved for exclusive use with the advanced staining solution. Lung cancer and malignant melanoma are major healthcare concerns worldwide, with lung cancer accountin...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch